Coya Therapeutics

0 followers


Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.

Industries

Headquarters

Stage

Employees

Links

Org chart

Howard Berman
CEO & Chairman

Howard Berman

Collapse
Adrian Hepner
President & Chief Medical Officer
Gregory MacMichael
Chief Technical Officer
John M. Centanni
VP Regulatory Affairs
Aaron Thome
Head, Neuroinflammation Platform
David Beers
Head, Biomarker Program
Arun Swaminathan
Chief Business Officer
Fred Grossman D.O., FAPA
President and Chief Medical Officer